With regards protection, both
methods to deliver the pcDNA.VP2 vaccine diminished the mortality
from the very first days post-challenge, which may be related
to the innate-immune response induced. Moreover, strong specific
protectionwas evident 30 days post-challenge, as demonstrated by
the levels of the neutralizing antibodies recorded and by the cumulative
mortality.